Skip to main content
SpringerLink
Log in
Book cover

Oral Antidiabetics pp 185–198Cite as

Toxicology of Sulfonylureas

  • Chapter

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 119))

Abstract

Since 1958, Hoechst AG, Frankfurt, and Boehringer Mannheim GmbH have synthesized and pharmacologically tested a large number of sulfonylurea analogues which elicit hypoglycemic activity in the milligram range and in some cases at less than 0.1mg/kg body weight. Glibenclamide (HB419) was chosen from a group of the most potent compounds for joint research in 1964 and introduced onto the market as Daonil by Hoechst and as Euglucon by Boehringer (Hebold et al. 1969a, b; Mitsukami et al. 1969).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Achelis JD, Hardebeck K (1955) Über eine neue blutzuckersenkende Substanz. Dtsch Med Wochenschr 80:1452–1455

    Article  PubMed  CAS  Google Scholar 

  • Ambrogi V, Bloch K, Daturi S, Griggi P, Logemann W, Mandelli V, Parenti MA, Rabini T, Usardi MM, Tommasini R (1971) Pharmacological study on a new oral antidiabetic: N-4-beta-(5-methylpryrazine-2-carboxamido)ethylebenzenesul-fonyl-n’-cyclohexylurea or K4024. Arzneimittelforschung 21(2):208–215.

    CAS  Google Scholar 

  • Baeder C, Sakaguchi T (1969) Teratologische Untersuchungen mit HB 419, Arzneimittel Forsch 1419–1420

    Google Scholar 

  • Bänder A (1971) Zur Pharmakologie und Toxikologie der blutzuckersenkenden Sulfonamide. Handbuch der experimentellen Pharmakologie. Springer, Berlin Heidelberg New York, pp 318–401

    Google Scholar 

  • Ballagi-Pordány G, Koltai M-Z, Aranyi Z, Pogátsa G (1990) Direct cardiovascular effect of hypoglycemic sulphonylurea compounds. Diabetologia 33 [Suppl]:A53

    Google Scholar 

  • Brown JD, Brown ME (1977) The effect of tolbutamide on contractility and cyclic adenosine 3’:5’-monophosphate concentration in the intact beating rat heart. J Pharmacol Exp Ther 200:166–173

    PubMed  CAS  Google Scholar 

  • Curtis GP, Setchfield J, Lucchesi BR (1975) The cardiac pharmacology of tolbutamide. J Pharmacol Exp Ther 194:264–273

    PubMed  CAS  Google Scholar 

  • Duhault J, Boulanger M, Tisserand F, Beregi L (1972) The pharmacology of S 1072, a new highly effective oral antidiabetic drug with unusual properties. Arzneimittelforschung (Drug Res) 22:1682–1685

    CAS  Google Scholar 

  • Dulin WE, Oster HL, McMahon FG (1961) A new high potency antidiabetic sulfonylurea [n-(l-hexahydro-l-azepinyl)-N’-p-tolylsulfonylurea]. Proc Soc Exp Biol 107:245–248

    Article  PubMed  CAS  Google Scholar 

  • Findlay I (1992) Effects of pH upon the inhibition by suphonylurea drugs of ATP-sensitive K+ channels in cardiac muscle. J Pharmacol Exp Ther 262:71–79

    PubMed  CAS  Google Scholar 

  • Heboid G (1971) Experimentelle, geschlechtsdifferente Beeinflussung der Langer-hans’schen Inseln des Pankreas. Habilitationsschrift, University of Heidelberg

    Google Scholar 

  • Heboid G, Scholz J, Schütz E, Czerwek H, Sagagushi T, Brunk R, Notdurft H, Kief H, Bäder C, Hartig F (1969a) Experimental investigations of the new sulfonylurea-derivate glibenclamide Hb 419. Horm Metab Res 1:4–10

    Google Scholar 

  • Heboid G, Scholz J, Schütz E, Czerwek H, Brunk R (1969b) Verträglichkeitsprüfungen von Hb 419 im Tierversuch. Arzneimittelforschung 19:1404–1413

    Google Scholar 

  • Herman EH, Krop S, Jordan W (1982) Tolbutamide enhancement of ouabain cardiotoxicity in rabbits. Pharmacology 24:111–117

    Article  PubMed  CAS  Google Scholar 

  • Hoffmann-La Roche (1985) Basic documentation on Glutril. Hoffmann-La Roche, Basel, pp 1–15

    Google Scholar 

  • Iida H, Kast A, Tsunenari Y (1976) Studies on the teratogenicity of a new sulfonylurea derivative (ARDF 26 SE) in rats and rabbits. Pharmocometrics 11:119–131

    CAS  Google Scholar 

  • Kast A, Tsunenari Y, Honma M, Nishikawa J, Shibata T, Torii M (1975) Toxico-logical tests of a new sulfonylurea derivate (ARDF 26 SE) in rats, mice and rabbits. Pharmacometrics 10:383–394

    CAS  Google Scholar 

  • Kiso To Rinsho (1972) Clinical report (Yubunsh Co). 6:1925

    Google Scholar 

  • Kleiss D, Rech M (1977) Langzeituntersuchungen an alloxandiabetischen Kaninchen — Stoff-wechselverhalten, Allgemeinbefinden, Kreislaufuntersuchungen und Organbefunde — unter chronischer Gabe von Tolbutamid und Methoxy-Methyl-Indolcarbonsäure. Dissertation, University of Heidelberg

    Google Scholar 

  • Krall LP (1984) Glyburide (DiaBeta®): a new second generation hypoglycemic agent. Clin Ther 6(6):746–762

    PubMed  CAS  Google Scholar 

  • Kramer JH, Lampson WG, Schaffer SW (1983) Effect of tolbutamide on myocadial anergy metabolism. Ann J Physiol 245:H313–H319

    Google Scholar 

  • Kramer M, Hecht G, Lanecker H, Harwart A, Richter KD, Gloxhuber C (1964) Pharmako-logie des 2-Benzolsulfonamido-5(β- methoxy-äthoxy)-pyrimidins (Glycodiazin), einer neuen blutzuckersenkenden Verbindung. Arzneimittelforschung 14:377–385

    PubMed  CAS  Google Scholar 

  • Lampson WG, Kramer JH, Schaffer SW (1985) Effect of tolbutamide on myocardial energy metabolism of the ischemic heart. Biochem Pharmacol 34:803–809

    Article  PubMed  CAS  Google Scholar 

  • Lebovitz HE, Melander A (1992) Sulfonylureas: basic aspects and clinical uses. In: Alberti KGMM, DeFronzo RA, Keen H, Zimmet P (eds) International textbook of diabetes mellitus. Wiley, New York

    Google Scholar 

  • Lee KC, Wilson RA, Randall DC, Altiere RJ, Kiritsy-Ray JA (1988) An analysis of the haemodynamic effects of tolbutamide in conscious dogs. Clin Exp Pharmacol Physiol 15:379–390

    Article  PubMed  CAS  Google Scholar 

  • Lorch E, Gey KF, Sommer P (1972) Glibornurid, ein neues hochwirksames Antidiabetikum Pharmakologische und biochemische Vergleichsuntersuchungen an verschiedenen Tierspezies und an tierexperimentellen Modellen. Arzneimittelforschung (Drug Res) 22(12a):2154–2163

    CAS  Google Scholar 

  • Maha GE, Kirtley WR, Root MA, Anderson RC (1962) Acetohexamide, preliminary report on a new oral hypoglycemic agent. Diabetes 11:83–90

    PubMed  CAS  Google Scholar 

  • McKean, Branz AJ (1992) Influence of ATP-sensitive potassium channel blocker on hypoxia-induced damage of isolated guinea pig heart. Gen Pharmacol 23: 921–923

    Article  PubMed  CAS  Google Scholar 

  • Mitsukami K, Myamoto M, Hayashi S, Kobayashi T, Sukurai M, Sakagushi T (1969) Toxikologische Untersuchungen von N-4-[2-(5-cholor-2-methoxy-benzamido)-acetyl]phenylsulfonyl-N-cyclohexylharnstoff (Hb 419). Arzneimittelforschung 19:1413–1419

    Google Scholar 

  • NCI report (1977a) Bioassay of acetohexamide for possible carcinogenicity (CAS no 968 81–0)

    Google Scholar 

  • NCI report (1977b) Bioassay of tolazamide for possible carcinogenicity (CAS no 1156–19-0)

    Google Scholar 

  • NCI Carcinogenesis Bioassay (1978) Chlorpropamide (NCITR* NCI-CG-TR-45,78); tolbutamide (NCITR* NCI-CG-TR-31,77)

    Google Scholar 

  • Pfeiffer EF (1984) Are the “second generation” oral hypoglycemic agents really different. Acta Diabetol Lat 21(l):l-32

    Google Scholar 

  • Renner HW, Münzinger R (1980) Mutagenicity of sulphonylureas. Mutat Res 77: 349–355

    Article  PubMed  CAS  Google Scholar 

  • Schad H, Heimisch W, Maier-Rudolph W, Mendier M (1993) Effect of glibenclamide on myocardial blood flow and function. Eur J Physiol 422 [Suppl 1]:R111

    Google Scholar 

  • Schaffer SW, Poole CG, Lampson WG, Kramer JH (1981) Effect of tolbutamide on the mechanical function of the isolated rat heart subjected to global ischemia. J Mol Cell Cardiol 13:341–345

    Article  PubMed  CAS  Google Scholar 

  • Schärer K, Hummler H (1971) Toxicological experiments with drugs of the sulfonylurea type in animals. In: Dubach UC, Bückert A (eds) Recent hypoglycemic sulfonylureas, mechanisms of action and clinical indications. Huber, Bern, pp 163–170

    Google Scholar 

  • Schneider JA, Salgado ED, Jäger D, Delahunt C (1959) The pharmacology of chlorpropamide. Ann N Y Acad Sci 74:427–442

    Article  PubMed  CAS  Google Scholar 

  • Scholz J, Bänder A (1956) Über die orale Behandlung des Diabetes mellitus mit N-[4-Methylbenzolsulfonyl]-N′-butylharnstoff (D860), Pharmakologie. Dtsch Med Wochenschr 81:825–826

    CAS  Google Scholar 

  • Tan BH, Wilson GL, Schaffer SW (1984) Effect of tolbutamide on myocardial metabolism and mechanical performance of the diabetic rat. Diabetes 33: 1138–1143

    Article  PubMed  CAS  Google Scholar 

  • Tettenborn D (1974) Zur Toxikologie von Glisoxepid, einem neuen oralen Antidiabetikum. Ergebnisse der Tieversuche. Arzneimittelforschung (Drug Res) 24:409–418

    CAS  Google Scholar 

  • University Group Diabetes Program (1970) A study of the effects of hypoglycemic agents on vascular complications in patients with adult onset. Diabetes 19 [Suppl II]:789–830

    Google Scholar 

  • Wales JK, Grant AM, Wolff FW (1971) The effect of tolbutamide on blood pressure. J Pharmacol Exp Ther 178:130–140

    PubMed  CAS  Google Scholar 

  • Warnik PR, Davis FB, Davis PJ, Mylotte KM, Blas SD (1986) Differential activities of tolbutamide, tolazamide, and glyburide in vitro on rabbit myocardial membrane Ca2+-transporting ATPase activity. Diabetes 35:1044–1048

    Article  Google Scholar 

  • Watson WAF, Petrie JC, Galloway DB, Bullock I, Gilbert JC (1976) In vivo cytogenetic activity of sulphonylurea drugs in man. Mutat Res 38:71–80

    Article  PubMed  CAS  Google Scholar 

  • Wu CF, Haider B, Ahmed SS, Oldewurtel HA, Lyons MM, Regan TJ (1977) The effects of tolbutamide on the myocardium in experimental diabetes. Circulation 55:200–205

    Article  PubMed  CAS  Google Scholar 

  • Yasuba M, Matsuoka N, Iida M, Maeda K, Nishiwaki T, Ueda N, Ohnishi K, Tatsumi H, Hashimoto M (1981). Acute, subacute, and long-term toxicity studies of gliclazide in diabetic animals. Yakuri To Chiryo 9(ll):4497–4520

    CAS  Google Scholar 

Download references

Authors
  1. F. Hartig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. H. Langer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. Rebel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. H. Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. Schütz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut für Klinische Pharmakologie, Bayer AG, Aprather Weg, 42096, Wuppertal, Germany

    Jochen Kuhlmann

  2. Krummacher Straße 200, 42115, Wuppertal, Germany

    Walter Puls

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Hartig, F., Langer, K.H., Rebel, W., Schmidt, F.H., Schütz, E. (1996). Toxicology of Sulfonylureas. In: Kuhlmann, J., Puls, W. (eds) Oral Antidiabetics. Handbook of Experimental Pharmacology, vol 119. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-09127-2_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-09127-2_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-62456-1

  • Online ISBN: 978-3-662-09127-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation